The 4-year durability and safety data de-risk the BIM-IOL System's Phase 3 program and support a potential 505(b)(2) NDA pathway. Watch for FDA alignment updates and Phase 3 enrollment milestones as the next catalysts.
Price Chart
Executive Summary
SpyGlass Pharma reported positive interim 4-year data from its first-in-human trial of the BIM-IOL System for glaucoma. The data showed a 37% reduction in mean intraocular pressure (IOP), 86% of patients remained off topical drops, and no product-related adverse events were reported. This is a significant clinical milestone for a pre-revenue biotech, supporting the ongoing Phase 3 program and potential 505(b)(2) NDA submission.
Key Facts
- 37% reduction in mean IOP across all dose groups (from 25.1 mmHg to 15.9 mmHg) at 4 years
- 86% (18 of 21) of evaluable patients remained off all topical IOP-lowering drops
- No product-related adverse events reported in 21 evaluable patients at 48 months
- Company plans to work with FDA toward 505(b)(2) NDA submission
- Ongoing Phase 3 clinical trials and long-term follow-up through 2029
Financial Impact
No financial figures provided; pre-revenue clinical-stage company. Positive data supports pipeline value and potential regulatory pathway.
Risk Factors
- Small sample size (N=21 evaluable) limits statistical power
- Phase 3 results may not replicate FIH trial outcomes
- Regulatory and commercial adoption risks remain for a novel drug-device combination
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001778922-26-000052 |
| Exhibit: exhibit991-8kprx101926.htm | 0001778922-26-000052 |
| Document: 0001778922-26-000052-index-headers.html | 0001778922-26-000052 |
| Document: 0001778922-26-000052-index.html | 0001778922-26-000052 |
| Document: 0001778922-26-000052.txt | 0001778922-26-000052 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 8-K | $26.16 $27.71 | ▲ +5.93% | ▲ +5.40% | $28.48 (+8.87%) |
Oct 19, 2026 7d ago | Press Release | $24.60 $26.16 | ▲ +6.34% | ▲ +6.01% | $28.48 (+15.77%) |
Oct 1, 2026 25d ago | 8-K | $26.50 $24.92 | ▼ −5.96% | ▼ −6.70% | $28.48 (+7.47%) |
Oct 1, 2026 25d ago | Press Release | $26.50 $24.92 | ▼ −5.96% | ▼ −6.70% | $28.48 (+7.47%) |
May 14, 2026 23w ago | 8-K | $23.21 $22.24 | ▼ −4.18% | ▼ −4.12% | $28.48 (+22.71%) |
Mar 26, 2026 30w ago | Press Release | $22.61 $23.37 | ▲ +3.36% | ▲ +3.72% | $28.48 (+25.96%) |
Mar 9, 2026 33w ago | Press Release | $27.12 $26.82 | ▼ −1.11% | ▼ −0.92% | $28.48 (+5.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers